WO2024200769 - TREATMENT OF NEUROLOGICAL DISORDERS WITH ALLICIN AND ANALOGUES THEREOF
National phase entry:
Publication Number
WO/2024/200769
Publication Date
03.10.2024
International Application No.
PCT/EP2024/058682
International Filing Date
28.03.2024
Title **
[English]
TREATMENT OF NEUROLOGICAL DISORDERS WITH ALLICIN AND ANALOGUES THEREOF
[French]
TRAITEMENT DE TROUBLES NEUROLOGIQUES AVEC DE L'ALLICINE ET DES ANALOGUES ASSOCIÉS
Applicants **
KATHOLIEKE UNIVERSITEIT LEUVEN
KU Leuven Research & Development Waaistraat 6 - Box 5105
3000 Leuven, BE
STICHTING AMSTERDAM UMC
De Boelelaan 1117
1081 HV Amsterdam, NL
Inventors
DE WITTE, Peter
Predikherenberg 25
3010 Kessel-Lo, BE
HEYLEN, Lise
Den Hert 33/7
2275 Wechelderzande, BE
LAGAE, Lieven
Boslaan 15A
3050 Oud-Heverlee, BE
COPMANS, Daniëlle
Bovenveld 35
3220 Holsbeek, BE
NY, Annelii
Karlsruhelaan 21
2400 Mol, BE
ARONICA, Eleonora
c/o De Boelelaan 1117
1081 HV Amsterdam, NL
MILLS, James
c/o De Boelelaan 1117
1081 HV Amsterdam, NL
Priority Data
23164608.4
28.03.2023
EP
23177651.9
06.06.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 991 | |
| EPO | Filing, Examination | 4639 | |
| Japan | Filing | 526 | |
| South Korea | Filing | 608 | |
| USA | Filing, Examination | 2635 |
Total: 9399 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to allicin and related compounds for use in the prevention or treatment of epilepsy.[French]
L'invention concerne de l'allicine et des composés apparentés destinés à être utilisés dans la prévention ou le traitement de l'épilepsie.